Catalyst
Slingshot members are tracking this event:
AbbVie Receives Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ABBV |
|
|
||||
Additional Information
- DIPG are highly aggressive and difficult to treat brain tumors found at the base of the brain
- Marks the first FDA Rare Pediatric Designation for an AbbVie investigational medicine
- In 2014, the FDA and European Medicines Agency granted ABT-414 Orphan Drug Designation for the treatment of glioblastoma and glioma in adults, respectively
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 11, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Abt-414, Diffuse Intrinsic Pontine Glioma, Pediatric Brain Tumor
